All In Biotech

Drug Trial Radar · NCT05211570

AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

A Phase 1/2 Study to Assess the Safety, Pharmacokinetics, and Efficacy of Daily Intravenous AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Last checked: Nov 19, 2026Latest source record: Oct 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

78

Planned (sponsor's estimate)

Start

Jun 1, 2022

Primary completion

Aug 2026

Study completion Dec 2026

Sponsor

Lead sponsor
AB ScienceIndustry
Sponsor type
Industry
First posted
Jan 27, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to define the safety and tolerability of AB8939 in patients with AML by determining the dose-limiting toxicities, the maximum tolerated dose, and the recommended dose for dose expansion study.

Conditions

  • Acute Myeloid Leukemia Refractory
  • Acute Myeloid Leukemia, in Relapse
  • Myelodysplastic Syndrome Acute Myeloid Leukemia

Interventions

  • AB8939Drug

    Intravenous injection (from an initial dose of 0.9 mg/m²)

  • VenetoclaxDrug

    the recommended starting dose for AML indication is 100 mg. Dose escalating regimen as per SmPC.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of dose limiting toxicity (DLT)Time frame: Up to 56 days

Locations

10 sites in 4 countries. Site status is shown where the registry gives one.

  • MD Anderson Cancer Center

    Houston, Texas · Not yet recruiting

  • Institut Paoli Calmettes

    Marseille, France · Not yet recruiting

  • National and Kapodistrian University of Athens NKUA · Department of Hematology and Bone marrow Transplantation Unit

    Athens, Greece · Recruiting

  • General University Hospital of Alicantet (Hospital General Universitario Dr. Balmis de Alicante)

    Alicante, Spain · Recruiting

  • Hospital San Pedro de Alcantara

    Cáceres, Spain · Recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, Spain · Recruiting

  • Hospital Universitario Quirónsalud

    Madrid, Spain · Recruiting

  • MD Anderson Cancer Center Madrid

    Madrid, Spain · Recruiting

  • Clínica Universidad de Navarra

    Pamplona, Spain · Recruiting

  • Virgen del Rocío University Hospital (Hospital Universitario Virgen del Rocío)

    Seville, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.